CD274 and head and neck squamous cell carcinoma: VERSATILE-002 (NCT04260126) is an open-label, non-randomized study evaluating the combination of PDS0101 and pembrolizumab in subjects with HPV16-positive R/M HNSCC in two cohorts: ICI-naïve expressing PD-L1 ≥ 1 and ICI-refractory.